×
About 6,115 results

ALLMedicine™ Portal Hypertension Center

Research & Reviews  2,183 results

Ultrasound Pressure Estimation for Diagnosing Portal Hypertension in Patients Undergoin...
https://doi.org/10.1002/jum.15897
Journal of Ultrasound in Medicine : Official Journal of T... Machado P, Gupta I et. al.

Dec 2nd, 2021 - Hepatic venous pressure gradient (HVPG) is considered the standard in quantifying portal hypertension, but can be unreliable in dialysis patients. A noninvasive ultrasound technique, subharmonic-aided pressure estimation (SHAPE), may be a valuable...

Impact of concurrent splenectomy and esophagogastric devascularization on surgical outc...
https://doi.org/10.1016/j.ejso.2021.11.118
European Journal of Surgical Oncology : the Journal of Th... Chen ZL, Yao LQ et. al.

Nov 29th, 2021 - Portal hypertension due to cirrhosis is common among patients with hepatocellular carcinoma (HCC). This study aimed to compare the outcomes of partial hepatectomy in patients with HCC and clinically significant portal hypertension (CSPH) with or w...

Ambroxol chaperone therapy for Gaucher disease type I-associated liver cirrhosis and po...
https://doi.org/10.2174/1871530321666211119145230
Endocrine, Metabolic & Immune Disorders Drug Targets; Zhang P, Zheng MF et. al.

Nov 23rd, 2021 - Gaucher disease (GD) is a rare autosomal recessive inherited disease caused by the deficiency of glucocerebrosidase and characterized by a broad spectrum of clinical manifestations, including hepatosplenomegaly, bone infiltration, and cytopenia. M...

Endoscopic Treatment of Esophageal Varices.
https://doi.org/10.1016/j.cld.2021.08.003
Clinics in Liver Disease; Zuckerman MJ, Elhanafi S et. al.

Nov 23rd, 2021 - Acute variceal bleeding is a complication of portal hypertension, usually due to cirrhosis, with high morbidity and mortality. There are 3 scenarios for endoscopic treatment of esophageal varices: prevention of first variceal bleed, treatment of a...

Endoscopic Ultrasound Evaluation of Portal Pressure.
https://doi.org/10.1016/j.cld.2021.10.001
Clinics in Liver Disease; Souto EO

Nov 23rd, 2021 - Portal hypertension is a complex syndrome with multiple clinical manifestations that develop in a variety of conditions and diseases. The spectrum of portal hypertension manifestations is wide and dependent on the physiologic site of increased por...

see more →

Guidelines  7 results

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PORTAL HYPERTENSION.
https://doi.org/10.1016/j.clinre.2021.101767
Clinics and Research in Hepatology and Gastroenterology; Thabut D, Weil D et. al.

Aug 1st, 2021 - Compensated advanced chronic liver disease (cACLD) describes the spectrum of advanced fibrosis/cirrhosis in asymptomatic patients at risk of developing clinically significant portal hypertension (CSPH, defined by a hepatic venous pressure gradient...

Non-invasive diagnosis and follow-up of primary biliary cholangitis.
https://doi.org/10.1016/j.clinre.2021.101770
Clinics and Research in Hepatology and Gastroenterology; Corpechot C, Heurgue A et. al.

Aug 1st, 2021 - Primary biliary cholangitis (PBC) is a chronic inflammatory disease of the intra-hepatic bile ducts [1]. It is characterised biologically by chronic cholestasis associated with the presence of specific autoantibodies, and histologically by lesions...

ACR Appropriateness Criteria® Radiologic Management of Portal Hypertension.
https://doi.org/10.1016/j.jacr.2021.02.013
Journal of the American College of Radiology : JACR; , Pinchot JW et. al.

May 8th, 2021 - Cirrhosis is a heterogeneous disease that cannot be studied as a single entity and is classified in two main prognostic stages: compensated and decompensated cirrhosis. Portal hypertension, characterized by a pathological increase of the portal pr...

AGA Clinical Practice Update on Management of Bleeding Gastric Varices: Expert Review.
https://doi.org/10.1016/j.cgh.2021.01.027
Clinical Gastroenterology and Hepatology : the Official C... Henry Z, Patel K et. al.

Jan 26th, 2021 - Management of bleeding gastric varices (GV) presents a unique challenge for patients with portal hypertension. Despite over thirty years of diagnostic and treatment advances standardized practices for bleeding GV are lacking and unsupported by ade...

Transjugular intrahepatic portosystemic stent-shunt in the management of portal hyperte...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306985
Gut Tripathi D, Stanley AJ et. al.

Mar 3rd, 2020 - These guidelines on transjugular intrahepatic portosystemic stent-shunt (TIPSS) in the management of portal hypertension have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  120 results

Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
https://clinicaltrials.gov/ct2/show/NCT04727307

Nov 18th, 2021 - Liver cancer is the sixth most common cancer and the third leading cause of death from cancer worldwide (source: Globocan 2018). Hepatocellular carcinoma (HCC) represents 80-90% of liver cancers. Percutaneous thermal ablation (PTA) is a validated ...

Evaluation of Patients With Liver Disease
https://clinicaltrials.gov/ct2/show/NCT00001971

Nov 18th, 2021 - This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various l...

Impact of Weight Loss in Cirrhosis With Obesity and MAFLD
https://clinicaltrials.gov/ct2/show/NCT05104541

Nov 11th, 2021 - Liver disease is one of the main causes of hospital admissions worldwide and the 12th leading cause of mortality in many countries. Among all etiologies (toxic-metabolites, viral, autoimmune, and genetic disorders), nonalcoholic fatty liver diseas...

A Novel Algorithm to Stratify Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108): An International, Multicenter Cohort Study
https://clinicaltrials.gov/ct2/show/NCT05100485

Oct 29th, 2021 - Compensated advanced chronic liver disease (cACLD) commonly indicates severe fibrosis and compensated cirrhosis at risk of developing clinically significant portal hypertension (CSPH) and hepatic decompensation.The presence of CSPH (defined as hep...

SHAPE of Portal Hypertension in Children
https://clinicaltrials.gov/ct2/show/NCT04720456

Oct 26th, 2021 - Early diagnosis of portal hypertension is difficult as symptoms rarely manifest until the later stages of liver disease. Both cirrhotic and non-cirrhotic portal hypertension can result in life-threatening complications, the most frequent of which ...

see more →

News  128 results

Incidence and Outcomes of Splanchnic Vein Thrombosis in Patients with Pancreatitis
https://www.medscape.com/viewarticle/962149

Nov 3rd, 2021 - Takeaway The incidence of splanchnic vein thrombosis (SVT) remains significant in patients with acute pancreatitis. Treatment with anticoagulants improved the rate of recanalisation but increased the risk of haemorrhagic complications, without inc...

HEPZATO Demonstrates Promising Preliminary Activity in Metastatic Ocular Melanoma
https://www.onclive.com/view/hepzato-demonstrates-promising-preliminary-activity-in-metastatic-ocular-melanoma

Oct 6th, 2021 - HEPZATO KIT (HEPZATO; melphalan hydrochloride for injection/hepatic delivery system) has demonstrated statistically significant benefit compared to best alternative care (BAC) in patients with liver-dominant metastatic ocular melanoma, according t...

Multidisciplinary Care to Provide Best Possible Outcomes in HCC
https://www.onclive.com/view/multidisciplinary-care-to-provide-best-possible-outcomes-in-hcc

Oct 6th, 2021 - Amit G. Singal, MD The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) for patients with hepatocellular carcinoma (HCC) highlights the need for multidisciplinary care because of the increased risk of gastrointestinal (GI) bleedi...

Experts Provide Real-World Advice for Molecular Testing in Gastrointestinal Malignancies
https://www.onclive.com/view/experts-provide-real-world-advice-for-molecular-testing-in-gastrointestinal-malignancies

Oct 6th, 2021 - Differences in germline and somatic BRCA mutations in pancreatic cancer, the role of molecular testing in hepatocellular carcinoma (HCC), and treatment options for patients with BRAF-mutant, microsatellite instability–high (MSI-H) colorectal cance...

FDA Restricts Ocaliva Use in Primary Biliary Cholangitis
https://www.medpagetoday.com/gastroenterology/generalhepatology/92819

May 27th, 2021 - FDA on Wednesday restricted the use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) due to the risk of serious liver injury in patients with advanced cirrhosis. Serious side effects, such as liver failure or the urgent need for ...

see more →

Patient Education  6 results see all →